Skip to main content
SpringerLink
Log in

Optimal management of major bleeding on DOACs: not only reversal agents

  • IM - COMMENTARY
  • Published:
Internal and Emergency Medicine Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Huisman MV, Rothman KJ, Paquette M, Teutsch C, Diener HC, Dubner SJ, Halperin JL, Ma CS, Zint K, Elsaesser A, Bartels DB, Lip GY, GLORIA-AF Investigators (2017) The changing landscape for stroke prevention in AF: findings from the GLORIA-AF registry phase 2. J Am Coll Cardiol 69(7):777–785

    Article  PubMed  Google Scholar 

  2. Ageno W, McCallun P, Haas S, Weitz JI, Angchaisuksiri P, Bounameaux H, Goldhaber SZ, Goto S, Kayani G, Dalsgaard Nielsen J, Mantovani LG, Schellong S, Turpie AGG, Prandoni P, Kakkar AK. Clinical characteristics and management of 10,329 patients with a confirmed diagnosis of venous thromboembolism: the GARFIELD-VTE registry. Abstract ASY 35.4, ISTH 2017

  3. Ruff CT, Giugliano RP, Braunwald E, Hoffman EB, Deenadayalu N, Ezekowitz MD, Camm AJ, Weitz JI, Lewis BS, Parkhomenko A, Yamashita T, Antman EM (2014) Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet 383(9921):955–962

    Article  PubMed  CAS  Google Scholar 

  4. van Es N, Coppens M, Schulman S, Middeldorp S, Büller HR (2014) Directoral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: evidence from phase 3 trials. Blood 124(12):1968–1975

    Article  PubMed  CAS  Google Scholar 

  5. Testa S, Ageno W, Antonucci E, Morandini R, Beyer-Westendorf J, Paciaroni M, Righini M, Sivera P, Verhamme P, Pengo V, Poli D, Plareti G (2018) Management of major bleeding and outcomes in patients treated with direct oral anticoagulants: results from the START-Event registry. Intern Emerg Med 13:1051–1058

    Article  PubMed  Google Scholar 

  6. Witt DM, Nieuwlaat R, Clark NP, Ansell J, Holbrook A, Skov J, Shehab N, Mock J, Myers T, Dentali F, Crowther MA, Agarwal A, Bhatt M, Khatib R, Riva JJ, Zhang Y, Guyatt G (2108) American Society of Hematology 2018 guidelines for management of venous thromboembolism: optimal management of anticoagulation therapy. Blood Adv 2(22):3257–3291  

    Article  PubMed  Google Scholar 

  7. Sheikh-Taha M (2018) Treatment of apixaban- and rivaroxaban-associated major bleeding using 4-factor prothrombin complex concentrate. Intern Emerg Med. https://doi.org/10.1007/s11739-018-1977-9

  8. Schulman S, Kearon C, Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis (2005) Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost 3(4):692–694

    Article  PubMed  CAS  Google Scholar 

  9. Khorsand N, Majeed A, Sarode R, Beyer-Westendorf J, Schulman S, Meijer K, Subcommittee on Control of Anticoagulation (2016) Assessment of effectiveness of major bleeding management: proposed definitions for effective hemostasis: communication from the SSC of the ISTH. J Thromb Haemost 14(1):211–214

    Article  PubMed  CAS  Google Scholar 

  10. Connolly SJ, Milling TJ Jr, Eikelboom JW, Gibson CM, Curnutte JT, Gold A, Bronson MD, Lu G, Conley PB, Verhamme P, Schmidt J, Middeldorp S, Cohen AT, Beyer-Westendorf J, Albaladejo P, Lopez-Sendon J, Goodman S, Leeds J, Wiens BL, Siegal DM, Zotova E, Meeks B, Nakamya J, Lim WT, Crowther M, ANNEXA-4 Investigators (2016) Andexanet alfa for acute major bleeding associated with factor Xa inhibitors. N Engl J Med 375(12):1131–1141

    Article  PubMed  PubMed Central  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Research Center on Thromboembolic Disorders and Antithrombotic Therapies, Department of Medicine and Surgery, School of Medicine, University of Insubria, U.O. Medicina 1, ASST Settelaghi, Viale Borri 57, 21100, Varese, Italy

    Silvia Galliazzo & Alessandro Squizzato

Authors
  1. Silvia Galliazzo
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Alessandro Squizzato
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Alessandro Squizzato.

Ethics declarations

Conflict of interest

Alessandro Squizzato received fees for lectures and/or advisory board meetings from Daiichi Sankyo, Pfizer, Bristol Myers Squibb, Bayer, Boehringer Ingelheim. Silvia Galliazzo, nothing to disclose.

Statement of human and animal rights

This article does not contain any studies with human participants or animals performed by any of the authors.

Informed consent

None.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Galliazzo, S., Squizzato, A. Optimal management of major bleeding on DOACs: not only reversal agents. Intern Emerg Med 14, 207–208 (2019). https://doi.org/10.1007/s11739-018-02020-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11739-018-02020-0

Search

Navigation